Survival in a randomised trial comparing two treatments for ovarian cancer
ovarianA data frame with 26 observations and the following variables
futimesurvival or censoring time
fustat0=censored, 1=death
ageage in years
resid.dsresidual disease present (1=no,2=yes)
rxtreatment group, 1= cyclophosphamide, 2= cyclophosphamide + adriamycin
ecog.psECOG performance status (1 is better)
Edmunson, J.H., Fleming, T.R., Decker, D.G., Malkasian, G.D., Jefferies, J.A., Webb, M.J., and Kvols, L.K., Different Chemotherapeutic Sensitivities and Host Factors Affecting Prognosis in Advanced Ovarian Carcinoma vs. Minimal Residual Disease. Cancer Treatment Reports, 63:241-47, 1979.